Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C3H5O2.Zn |
Molecular Weight | 211.55 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zn++].CCC([O-])=O.CCC([O-])=O
InChI
InChIKey=XDWXRAYGALQIFG-UHFFFAOYSA-L
InChI=1S/2C3H6O2.Zn/c2*1-2-3(4)5;/h2*2H2,1H3,(H,4,5);/q;;+2/p-2
Molecular Formula | Zn |
Molecular Weight | 65.409 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C3H5O2 |
Molecular Weight | 73.0706 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfCurator's Comment: description was created based on several sources, including
http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
Sources: http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf
Curator's Comment: description was created based on several sources, including
http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
There is no available information related any biological or pharmacutical application of AMMONIUM PENTACHLOROZINCATE
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25374537 | https://www.ncbi.nlm.nih.gov/pubmed/15639165https://www.ncbi.nlm.nih.gov/pubmed/2307275https://www.ncbi.nlm.nih.gov/pubmed/10721938http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
Curator's Comment: Glucarpidase hydrolyzes the methotrexate in the blood but cannot cross the blood-brain barrier, nor can it break down intracellular methotrexate.
Originator
Sources: http://sciencing.com/uses-zinc-carbonate-7889200.htmlhttps://www.webelements.com/zinc/history.htmlhttp://www.drugdevelopment-technology.com/projects/voraxaze-glucarpidase-for-the-treatment-of-toxic-plasma-methotrexate-concentrations/
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612426 |
|||
Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083 |
|||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783 |
|||
Target ID: CHEMBL2364710 |
|||
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194 |
|||
Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | CORTROPHIN-ZINC Approved UseTreatment of ulcerative colitis and other colonic disorders. Launch Date-4.55328006E11 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Secondary | VORAXAZE Approved UseIndicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date1.32675836E12 |
|||
Primary | VUSION Approved UseINDICATIONS AND USAGE
VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when
complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or
budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal
culture for Candida albicans is not adequate evidence of candidal infection since colonization
with C. albicans can result in a positive culture. The presence of candidal infection should be
established by microscopic evaluation prior to initiating treatment.
VUSION Ointment should be used as part of a treatment regimen that includes measures
directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and
frequent diaper changes. Launch Date1.140048E12 |
|||
Primary | ZINC OXIDE Approved UseUnknown |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
PubMed
Title | Date | PubMed |
---|---|---|
In vitro activity of zinc salts against human rhinoviruses. | 1987 Apr |
|
A medicated polycarboxylate cement to prevent complications in composite resin therapy. | 1990 Jan |
|
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates. | 1993 Aug |
|
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds. | 1994 Dec |
|
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. | 1997 Feb |
|
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. | 2000 Sep |
|
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function. | 2004 Jul 30 |
|
High-throughput computational and experimental techniques in structural genomics. | 2004 Oct |
|
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections]. | 2005 |
|
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2. | 2005 Apr 27 |
|
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise. | 2005 May |
|
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet. | 2005 Nov-Dec |
|
Characterization and inhibition of SARS-coronavirus main protease. | 2006 |
|
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report. | 2006 Apr |
|
Elevated cortical zinc in Alzheimer disease. | 2006 Jul 11 |
|
The effect of Ramadan on maternal nutrition and composition of breast milk. | 2006 Jun |
|
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats. | 2006 May |
|
Zinc homeostasis in aging: two elusive faces of the same "metal". | 2006 Summer |
|
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing. | 2010 Dec |
|
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. | 2010 Dec 1 |
|
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles. | 2010 Dec 15 |
|
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells. | 2010 Jul |
|
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. | 2010 Oct |
|
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways. | 2011 Dec |
|
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells. | 2011 Jul |
|
Zinc induces chemokine and inflammatory cytokine release from human promonocytes. | 2011 Nov 30 |
|
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. | 2012 Apr |
|
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity. | 2012 Feb |
|
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface. | 2012 Feb |
|
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung. | 2012 Jun 25 |
|
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells. | 2012 Mar |
|
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide. | 2012 Mar |
|
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts. | 2012 May 5 |
|
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation. | 2013 Dec |
|
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. | 2013 Jan |
|
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils. | 2013 Jul 31 |
|
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells. | 2013 Mar |
|
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties. | 2013 Nov 25 |
|
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation. | 2013 Sep |
|
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling. | 2014 Apr |
|
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles. | 2014 Jan |
|
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation. | 2014 Jul 1 |
|
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line. | 2014 Mar 3 |
|
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity. | 2014 May 16 |
|
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design. | 2015 |
|
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity. | 2015 Apr 2 |
|
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode. | 2016 Mar 5 |
|
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process. | 2016 Oct |
|
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations. | 2016 Sep 21 |
|
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass. | 2017 May 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10978858
Rats: The dose of zinc hydroxide administered to each rat was 85 mg/kg and
represented 40% of the recommended daily allowance of a male
adult human. This dose was administered in water solution at a
final volume of 1 mL per rat.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1320875
Zinc hydroxide (1 mM) stimulates superoxide production by rat alveolar macrophages, as determined by CLA-dependent chemiluminescence.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:32:01 UTC 2023
by
admin
on
Wed Jul 05 22:32:01 UTC 2023
|
Record UNII |
81PXA87XVC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID10890510
Created by
admin on Wed Jul 05 22:32:01 UTC 2023 , Edited by admin on Wed Jul 05 22:32:01 UTC 2023
|
PRIMARY | |||
|
M11623
Created by
admin on Wed Jul 05 22:32:01 UTC 2023 , Edited by admin on Wed Jul 05 22:32:01 UTC 2023
|
PRIMARY | Merck Index | ||
|
81PXA87XVC
Created by
admin on Wed Jul 05 22:32:01 UTC 2023 , Edited by admin on Wed Jul 05 22:32:01 UTC 2023
|
PRIMARY | |||
|
11189
Created by
admin on Wed Jul 05 22:32:01 UTC 2023 , Edited by admin on Wed Jul 05 22:32:01 UTC 2023
|
PRIMARY | |||
|
557-28-8
Created by
admin on Wed Jul 05 22:32:01 UTC 2023 , Edited by admin on Wed Jul 05 22:32:01 UTC 2023
|
PRIMARY | |||
|
209-167-6
Created by
admin on Wed Jul 05 22:32:01 UTC 2023 , Edited by admin on Wed Jul 05 22:32:01 UTC 2023
|
PRIMARY | |||
|
1061
Created by
admin on Wed Jul 05 22:32:01 UTC 2023 , Edited by admin on Wed Jul 05 22:32:01 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |